首页 产品目录 分子砌块 按反应类型 1,2,4-三唑 (E)-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine (2S,3S)-2,3-dihydroxysuccinate

(E)-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine (2S,3S)-2,3-dihydroxysuccinate

(E)-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine (2S,3S)-2,3-dihydroxysuccinate

产品编号 :
Cas No. :
包装规格 纯度 目录价 会员专享价 库存 数量

抱歉,暂无牌价信息

晶智化学产品均仅供科研使用。在任何情况下,我们均不提供用于动物或人体用途的产品或服务。

基础信息

CAS No.

1291074-87-7

英文名称

(E)-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine (2S,3S)-2,3-dihydroxysuccinate

别名

(E)-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine,L-(+)-Tartaric acid;ENMD-2076 (Tartrate);ENMD-2076 L-(+)-Tartaric acid;ENMD-2076 tartrate (ENMD 2076

标准英文名

(E)-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine (2S,3S)-2,3-dihydroxysuccinate

分子式

C25H31N7O6

分子量

525.57

精确分子量

525.23

SMILES

CC1=CC(NC2=CC(N3CCN(C)CC3)=NC(/C=C/C3=CC=CC=C3)=N2)=NN1.O=C(O)[C@@H](O)[C@H](O)C(=O)O

标准SMILES

CN1CCN(CC1)C1C=C(NC2C=C(C)NN=2)N=C(/C=C/C2C=CC=CC=2)N=1.OC(=O)[C@@H](O)[C@H](O)C(O)=O

用途

ENMD-2076 L-(+)-tartrate is a selective inhibitor of Aurora A and VEGFR (Flt3) with IC50 values of 14 nM and 1.86 nM, respectively; it exhibits 25-fold selectivity for Aurora A over Aurora B and shows weaker activity against VEGFR2/KDR, VEGFR3, FGFR1, FGFR2, and PDGFRα. It demonstrates potent anti-proliferative effects against a broad panel of human solid tumor and hematologic cancer cell lines (IC50: 0.025–0.7 μM), inducing apoptosis and G2/M cell cycle arrest. ENMD-2076 inhibits tumor growth or causes tumor regression in xenograft models derived from breast cancer, colon cancer, melanoma, leukemia, and multiple myeloma. It exhibits significant cytotoxicity against multiple myeloma cell lines (IM9, ARH-77, U266, RPMI8226, MM.1S, MM.1R, NCI-H929) and primary cells (IC50: 2.99–7.06 μM), while showing low cytotoxicity toward hematopoietic progenitor cells. The compound suppresses the PI3K/Akt pathway and downregulates anti-apoptotic proteins survivin and XIAP. In vivo, ENMD-2076 sustains inhibition of FLT3, VEGFR2/KDR, and FGFR1/2 activation in HT29 xenografts; in MDA-MB-231 xenografts, it inhibits angiogenesis and promotes vascular regression. Oral administration of ENMD-2076 at 50, 100, or 200 mg/kg daily significantly suppresses tumor growth in H929 human plasmacytoma xenografts, reduces phosphorylated Histone H3 (pH3), Ki-67, and angiogenesis, and enhances cleaved caspase-3 levels. It is currently in Phase 2 clinical development.

InChIKey

KGWWHPZQLVVAPT-PCWHHUEVSA-N

安全信息

SureRoute逆合成路线

1.  1291074-87-7 逆合成路线 1

ACJACD865
34352-59-5
—
—
ACJXRU511
1291074-87-7
来源: SureRoute

2.  1291074-87-7 逆合成路线 2

ACJACD865
34352-59-5
—
—
ACJXRU511
1291074-87-7
来源: SureRoute

3.  1291074-87-7 逆合成路线 3

—
—
—
—
ACJXRU511
1291074-87-7
来源: SureRoute
评论 0
我是晶智Agent,
您的化学小助手